Antitubercular nanocarrier monotherapy: study of in vivo efficacy and pharmacokinetics for rifampicin

0522432 - ÚMCH 2021 RIV NL eng J - Článek v odborném periodiku
Trousil, Jiří - Pavliš, O. - Kubíčková, P. - Škorič, M. - Marešová, V. - Pavlova, Ewa - Knudsen, K. D. - Dai, Y.-S. - Zimmerman, M. - Dartois, V. - Fang, J.-Y. - Hrubý, Martin
Antitubercular nanocarrier monotherapy: study of in vivo efficacy and pharmacokinetics for rifampicin.
Journal of Controlled Release. Roč. 321, 10 May (2020), s. 312-323. ISSN 0168-3659. E-ISSN 1873-4995
Grant CEP: GA ČR(CZ) GA17-07164S; GA ČR(CZ) GA17-09998S; GA MŠMT(CZ) LO1507
Grant ostatní: AV ČR(CZ) TWN-18-10; AV ČR(CZ) VAJVA-19-55
Institucionální podpora: RVO:61389013
Klíčová slova: tuberculosis * nanoparticles * drug delivery system
Obor OECD: Polymer science
Impakt faktor: 9.776, rok: 2020
Způsob publikování: Omezený přístup
https://www.sciencedirect.com/science/article/pii/S0168365920301164?via%3Dihub

Tuberculosis represents a major global health problem for which improved approaches are needed to shorten the course of treatment and to combat the emergence of resistant strains. The development of effective and safe nanobead-based interventions can be particularly relevant for increasing the concentrations of antitubercular agents within the infected site and reducing the concentrations in the general circulation, thereby avoiding off-target toxic effects. In this work, rifampicin, a first-line antitubercular agent, was encapsulated into biocompatible and biodegradable polyester-based nanoparticles. In a well-established BALB/c mouse model of pulmonary tuberculosis, the nanoparticles provided improved pharmacokinetics and pharmacodynamics. The nanoparticles were well tolerated and much more efficient than an equivalent amount of free rifampicin.
Trvalý link: http://hdl.handle.net/11104/0307136